ANNX:NASDAQ, Annexon, Inc.

ANNX stock overview

Annexon, Inc. (ANNX:NASDAQ) closed at $3.10 on November 20, 2026, down 9.09% on the day. The stock trades 56.8% below its 52-week high of $7.18 and 1.0% above its 52-week low of $3.07. Over the past year, it lost 27.4%. Annexon, Inc. is part of the Health Care sector.

Key figures

Price
$3.10
Day change
-9.09%
Volume
4,454,126
Average volume
3,317,345
Market cap
591M+
52-week range
$3.07 – $7.18
50-day average
$3.94
200-day average
$5.04

Price action over the past year

In 252 trading sessions since November 20, 2025, ANNX closed higher on 106 days (42%). Its best day was October 19, 2026 (+17.60%) and its worst was March 12, 2026 (-9.78%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

ANNX news

About Annexon, Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.

Similar stocks

Find more stocks like ANNX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.